Literature DB >> 18090892

Refractive enhancement following presbyopia-correcting intraocular lens implantation.

Marian Sue Macsai1, Bruno Machado Fontes.   

Abstract

PURPOSE OF REVIEW: Presbyopia-correcting intraocular lenses are widely available. Residual ametropia is one of the most common issues that can result in patient dissatisfaction. Options for correcting refractive surprises include piggyback intraocular lens implantation, corneal incisional surgery and laser correction. Excimer laser surgery is a safe and predictable method to correct residual amounts of ametropia in pseudophakic patients with monofocal intraocular lenses; however, there is scant published literature regarding this technique. RECENT
FINDINGS: Presbyopia-correcting intraocular lenses require emmetropia for the best visual outcome, as small amounts of astigmatism or residual refractive errors can limit their visual performance. Laser-assisted in-situ keratomileusis and photorefractive keratectomy are safe and effective results in pseudophakic patients. Surgeons can refine the refractive outcome after intraocular lens implantation with the excimer laser to achieve better results and higher patient satisfaction.
SUMMARY: Excimer laser corneal surgery for fine-tuning residual ametropia after presbyopia-correcting intraocular lenses is a safe adjunct treatment to increase patient satisfaction. Which technique (photorefractive keratectomy or laser-assisted in-situ keratomileusis) to use depends on surgeon preference and patient characteristics, as both demonstrate similar results in published literature. Knowledge of all available refractive methods and technologies are crucial for improving outcomes in these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18090892     DOI: 10.1097/ICU.0b013e3282f14d9f

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  13 in total

1.  Corrective Techniques and Future Directions for Treatment of Residual Refractive Error Following Cataract Surgery.

Authors:  Majid Moshirfar; Michael V McCaughey; Luis Santiago-Caban
Journal:  Expert Rev Ophthalmol       Date:  2014-12

2.  [Bioptics with multifocal lenses and Lasek].

Authors:  A Liekfeld; L Friederici; P Rieck
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

3.  Implantable collamer lens for residual refractive error after corneal refractive surgery.

Authors:  Xun Chen; Xiao-Ying Wang; Xi Zhang; Zhi Chen; Xing-Tao Zhou
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

4.  [A new toric diffractive multifocal lens for refractive surgery].

Authors:  A Liekfeld; N Torun; L Friederici
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

5.  Visual Performance of Tecnis ZM900 Diffractive Multifocal IOL after 2500 Implants: A 3-Year Followup.

Authors:  Leonardo Akaishi; Rodrigo Vaz; Graziela Vilella; Rodrigo C Garcez; Patrick F Tzelikis
Journal:  J Ophthalmol       Date:  2010-10-05       Impact factor: 1.909

6.  Dissatisfaction after multifocal intraocular lens implantation.

Authors:  Maria A Woodward; J Bradley Randleman; R Doyle Stulting
Journal:  J Cataract Refract Surg       Date:  2009-06       Impact factor: 3.351

7.  Predicting the necessity of LASIK enhancement after cataract surgery in patients with multifocal IOL implantation.

Authors:  Pinakin Gunvant; Anna Ablamowicz; Subba Gollamudi
Journal:  Clin Ophthalmol       Date:  2011-09-08

Review 8.  Corneal-Based Surgical Presbyopic Therapies and Their Application in Pseudophakic Patients.

Authors:  Grace L Paley; Roy S Chuck; Linda M Tsai
Journal:  J Ophthalmol       Date:  2016-03-09       Impact factor: 1.909

9.  Small-aperture intraocular lens tolerance to induced astigmatism.

Authors:  Robert Edward Ang
Journal:  Clin Ophthalmol       Date:  2018-09-04

10.  Photorefractive keratectomy for correcting residual refractive error following cataract surgery with premium intraocular lens implantation.

Authors:  Yuan-Yao Fan; Chi-Chin Sun; Hung-Chi Chen; David Hui-Kang Ma
Journal:  Taiwan J Ophthalmol       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.